Rituximab versus Tocilizumab in anti-TNF inadequate responder patients with Rheumatoid Arthritis (R4RA): a stratified, biopsy-driven, multi-centre, randomised, open label, controlled clinical trial – 16 week outcomes

Frances Humby, Patrick Durez, Maya Buch, Myles J Lewis, Hasan Rizvi, Felice Rivellese, Alessandra Nerviani, Giovanni Giorli, Arti Mahto, Carlomaurizio Montecucco, Bernard R Lauwerys, Nora Ng, Pauline Ho, Michele Bombardieri, Vasco C Romão, P Verschueren, Stephen Kelly, Pier Paolo Sainaghi, Nagui Gendi, Bhaskar DasguptaAlberto Cauli, Piero Reynolds, Juan D Cañete, R Moots, Taylor Peter, Christopher J Edwards, John Isaacs, Peter Sasieni, Ernest Choy, Costantino Pitzalis

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalThe Lancet
Publication statusPublished - 2020

Cite this